By the third week of experimental malaria, α-IFNAR treatment resulted in 2 to 4-fold increases in the number of P. yoelii infection-induced (S1B Fig) splenic GL7+CD95+ CD19+ GC B cells (Fig 1C and 1D). The gene discussed is FAS; the disease is malaria.